ICE Bioscience Posters

Download

Drug resistance is a major challenge in cancer therapy, often causing relapse after initial successful treatment. Exploring resistance mechanisms and developing new treatments are key goals in oncology. Several promising targets for anticancer drug development have been identified or are under active investigation. For instance, KRAS mutations are prevalent in pancreatic, colorectal, and lung cancers, driving uncontrolled cell proliferation. DNA damage repair (DDR) mechanisms normally maintain genomic stability by repairing DNA damage, but defects in DDR pathways can make cancer cells more susceptible to targeted therapies like PARP inhibitors. EGFR resistance is frequently observed in clinical settings, and the emerging field of antibody-drug conjugate (ADC) therapies is also encountering drug resistance challenges. Drug-resistant cell lines are valuable tools for studying these resistance mechanisms and discovering novel therapies.